Table 2. Plasma levels of TF activity and concentration, (TF) pathway inhibitor activity and concentration (TFPI), TF/TFPI activity and concentration ratios, t-PA, PAI-1 in patients with BrCa as well as in subjects free of BrCa depending on coexisting diseases.

Coagulation assays (units)	BrCa patients	BrCa patients free of coexisting disease	Subjects free of BrCa	Subjects free of BrCa and coexisting diseases	P-value
	Group I	Group II	Group III	Group IV	I vs II	I vs III	I vs IV	II vs IV
TF activity (pM)	14.01	16.29	13.10	12.69	P=0.2358	P=0.0938	P=0.0767	P=0.0049
	11.17/25.56	12.31/29.18	10.36/18.59	10.36/18.45
TF concentration (pg/ml)	535.40	535.40	116.65	116.65	P=0.9359	P<0.0001	P<0.0001	P<0.0001
	400.86/710.40	417.04/670.18	90.90/183.44	90.90/167.61
TF/TFPI activity ratio	10.79	15.42	10.78	10.20	P=0.2615	P=0.1741	P=0.1054	P=0.0064
	7.48/25.81	9.15/28.93	7.19/14.91	6.86/14.45
TFPI activity (U/ml)	1.32	1.23	1.30	1.57	P=0.5449	P=0.3201	P=0.1574	P=0.0379
	1.10/1.50	1.02/1.40	0.90/1.78	0.90/1.81
TFPI concentration (ng/ml)	44.58	43.80	77.18	75.53	P=0.6422	P<0.0001	P<0.0001	P<0.0001
	37.12/60.32	35.94/59.88	67.85/84.18	67.85/84.18
TF/TFPI concentration ratio	10.76	11.50	1.56	1.56	P=0.7881	P<0.0001	P<0.0001	P<0.0001
	8.67/17.05	8.72/18.49	1.12/2.67	1.17/2.49
t-PA concentration(ng/ml)	5.19	4.97	4.59	4.54	P=0.7345	P=0.3593	P=0.2859	P=0.5434
	3.94/6.70	3.89/6.39	3.12/6.42	2.99/6.29
PAI-1 concentration (ng/ml)	37.38	38.54	35.32	35.14	P=0.7421	P=0.2565	P=0.1914	P=0.1604
	27.87/47.43	27.08/50.57	21.17/51.51	21.17/49.62

Significant differences between groups are denoted by bold P-values.